We are monitoring the impact of COVID-19 on APAC HIV Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1983
Share on
Share on

Asia Pacific HIV Therapeutics Market Research Report – Segmented By Type, Application and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Growth, Trends and Forecast | 2019 - 2024

Pulished: February, 2020
ID: 1983
Pages: 135

The size of the APAC HIV Therapeutics Market was worth USD 2.33 billion in 2019 and estimated to be growing at a CAGR of 2.1%, to reach USD 2.59 billion by 2024.

The human immunodeficiency virus (HIV) refers to a kind of retrovirus that causes (AIDS). HIV affects some immune cells and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases.

HIV infection has no cure however there are medicines that help to balance out or decrease this infection so it doesn't prompt AIDS. HIV therapeutics market is developing at a significant rate because of increment in the HIV infected cases and developing awareness about the same.

Major Driving factors are the increasing number of HIV affected cases, an innovative advancement in HIV diagnosis and therapeutics, ascend in research exercises for developing HIV immunizations and not aware of the methods of transmission of the infection. Moreover, increasing awareness about the accessibility of HIV therapeutics in the market and cost-effective sedate treatments for HIV are driving the Asia Pacific HIV Therapeutics Market.

Be that as it may, different variables, for example, the disappointment of treatment sometimes, absence of gifted experts and presentation of non-specific medications in the market are major restraints the Asia Pacific HIV Therapeutics Market.

This research report is segmented &b sub-segmented the market into the following categories:

  • By Type: Nucleoside/Tide Reverse Transcriptase Inhibitors, Nucleoside/Tide Analogues, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors, CCR5 Inhibitors and Fusion Inhibitors
  • By Application: HIV Type-1 and HIV Type-2
  • By Country: India, China, Japan, South Korea,  Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Regionally, the Asian, African and South American areas are developing markets as of now contributing under 20% partake in the worldwide HIV market. The current development of the market in the Asia Pacific is, however, a positive sign for potential makers, with whatever remains of the world after a comparable example. The Asia Pacific is anticipated to be the fastest developing regional section and will hold its position over the forecast period inferable from the upgrading medicinal services foundation and presence of appropriate government activities favoring development.

Companies playing a key role in the APAC HIV Therapeutics Market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences.

1.Introduction                                                                  

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Drug Class                                                   

                                5.1.1 Introduction                                           

                                5.1.2 integrase inhibitor                                               

                                5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor                                         

                                5.1.4  non-nucleoside turn around transcriptase inhibitor                                             

                                5.1.5 HIV-1 protease inhibitor                                    

                                5.1.6 pharmacokinetic enhancer                                              

                                5.1.7 passage inhibitor                                  

                                5.1.8  Y-o-Y Growth Analysis, Drug class                                                

                                5.1.9  Market Attractiveness Analysis, Drug class                                              

                                5.1.10  Market Share Analysis, Drug class                                              

                5.2 Application                                                 

                                5.2.1 Introduction                                           

                                5.2.2 HIV Type-1                                              

                                5.2.3 HIV Type-2                                              

                                5.2.4 Y-o-Y Growth Analysis, Application                                               

                                5.2.5 Market Attractiveness Analysis, Application                                             

                                5.2.6 Market Share Analysis, Application                                              

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 Drug Class                            

                                                6.1.3.3 HIV TYPE 1&2                      

                                6.1.4  Market Attractiveness Analysis                                     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 Drug Class                            

                                                6.1.4.3 HIV TYPE 1&2                      

                                6.1.5  Market Share Analysis                                      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 Drug Class                            

                                                6.1.5.3 HIV TYPE 1&2                      

                6.2 China                                                             

                6.3 India                                                              

                6.4 Japan                                                            

                6.5 South Korea                                                               

                6.6 Australia                                                      

7.Strategic Analysis                                                                        

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8.Market Leaders' Analysis                                                                         

                8.1 Athersys                                                      

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 StemCells                                                    

                8.3 Cryo Cell International                                                           

                8.4 Geron Corporation                                                  

                8.5 Mesoblast                                                   

                8.6 Aastrom Biosciences                                                              

                8.7 Celgene Corporation                                                              

                8.8 Invitrogen                                                   

                8.9 Cytori Therapeutics                                                 

                8.10 Retractable Technologies                                                   

9.Competitive Landscape                                                                            

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10.Market Outlook and Investment Opportunities                                                                          

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Asia-Pacific HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  2. Asia-Pacific Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019 - 2024 ( USD Million )
  3. Asia-Pacific Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  4. Asia-Pacific Protease inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  5. Asia-Pacific Integrase [strand transfer] inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  6. Asia-Pacific Fusion inhibitors  Market By Region, From 2019 - 2024 ( USD Million )
  7. Asia-Pacific HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  8. Asia-Pacific HIV Type 1 Market By Region, From 2019 - 2024 ( USD Million )
  9. Asia-Pacific HIV Type 2 Market By Region, From 2019 - 2024 ( USD Million )
  10. Japan HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  11. Japan HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  12. China HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  13. China HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  14. India HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  15. India HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  16. Australia HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  17. Australia HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  18. South Korea HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  19. South Korea HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample